Genus reports strong annual results with 24% profit increase

Genus PLC reported robust financial results for fiscal year 2025, with adjusted profit before tax increasing 24% to £74.3 million and adjusted operating profit rising 19% to £93.1 million, driven by strong performance in its porcine and bovine segments. The company generated record free cash flow of £40.9 million and achieved a significant milestone with FDA approval for its PRRS-resistant pig gene edit in April 2025. Strategically, Genus signed agreements for a Chinese joint venture with Beijing Capital Agribusiness, securing a $160 million cash payment, and projects significant profit growth for FY26, alongside a reduced net debt of £228.2 million.

Analysis

Genus PLC reported a robust set of fiscal year 2025 results, demonstrating strong profitability, record cash generation, and significant strategic progress. Adjusted profit before tax surged 24% to £74.3 million, underpinned by 5% constant currency revenue growth and operational improvements across its porcine (PIC) and bovine (ABS) divisions. The company's cash flow profile improved dramatically, registering a record free cash flow of £40.9 million—a sharp reversal from the £3.2 million outflow in the prior year—and a cash conversion rate of 114%. This operational strength facilitated deleveraging, with the net debt to adjusted EBITDA ratio improving to a healthier 1.5x from 2.0x. Critically, the period included two major catalysts for future growth: the April 2025 FDA approval for its PRRS-resistant gene-edited pig and a strategic agreement for a Chinese joint venture that includes a $160 million cash payment. Coupled with management's guidance for "significant growth" in FY2026, these developments position the company on a solid footing, even as the board maintained the dividend, signaling a focus on reinvestment.

Key Decisions for Investors

• The combination of a 24% increase in adjusted profit, record free cash flow, and a positive outlook for FY2026 validates the company's operational execution and supports a constructive investment thesis.
• Investors should re-evaluate their valuation models to account for two significant de-risking events: the FDA approval of the PRRS-resistant pig, which opens a major new market, and the $160 million cash infusion from the China JV, which strengthens the balance sheet and accelerates growth in a key region.
• While the outlook is strong, it is prudent to monitor the commercialization timeline of the gene-edited product in the U.S. and the integration of the Chinese JV, as successful execution on these fronts is critical to realizing the guided profit growth.